These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1411 related items for PubMed ID: 15201414

  • 1. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T.
    N Engl J Med; 2004 Jun 17; 350(25):2572-81. PubMed ID: 15201414
    [Abstract] [Full Text] [Related]

  • 2. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
    Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE.
    J Clin Pharmacol; 2007 Sep 17; 47(9):1119-28. PubMed ID: 17766699
    [Abstract] [Full Text] [Related]

  • 3. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep 17; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 4. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years.
    Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin M, Lehane PB, Agarwal S.
    Rheumatology (Oxford); 2006 Dec 17; 45(12):1505-13. PubMed ID: 17062648
    [Abstract] [Full Text] [Related]

  • 5. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
    Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, DANCER Study Group.
    Arthritis Rheum; 2006 May 17; 54(5):1390-400. PubMed ID: 16649186
    [Abstract] [Full Text] [Related]

  • 6. B cells in rheumatoid arthritis: from hypothesis to the clinic.
    Keystone EC.
    Rheumatology (Oxford); 2005 May 17; 44 Suppl 2():ii8-ii12. PubMed ID: 15851525
    [Abstract] [Full Text] [Related]

  • 7. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ.
    N Engl J Med; 1999 Jan 28; 340(4):253-9. PubMed ID: 9920948
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
    Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S, Yin M, Kelman A.
    J Rheumatol; 2010 May 28; 37(5):917-27. PubMed ID: 20194448
    [Abstract] [Full Text] [Related]

  • 9. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D.
    Arthritis Rheum; 2002 Mar 28; 46(3):614-24. PubMed ID: 11920396
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F.
    Arthritis Rheum; 2007 Dec 28; 56(12):3896-908. PubMed ID: 18050221
    [Abstract] [Full Text] [Related]

  • 11. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan 28; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 12. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
    Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH, Paediatric Rheumatology International Trials Organisation, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2007 Sep 28; 56(9):3096-106. PubMed ID: 17763439
    [Abstract] [Full Text] [Related]

  • 13. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V.
    Arthritis Rheum; 2004 Feb 28; 50(2):364-71. PubMed ID: 14872477
    [Abstract] [Full Text] [Related]

  • 14. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M.
    J Rheumatol; 2008 Jan 28; 35(1):20-30. PubMed ID: 18050385
    [Abstract] [Full Text] [Related]

  • 15. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
    Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, METGO Study Group.
    Arthritis Rheum; 2005 May 28; 52(5):1360-70. PubMed ID: 15880810
    [Abstract] [Full Text] [Related]

  • 16. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
    Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I.
    J Rheumatol; 2006 Jan 28; 33(1):37-44. PubMed ID: 16395748
    [Abstract] [Full Text] [Related]

  • 17. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N, Gossec L, Dieudé P, Meyer O, Dougados M, Kahan A, Allanore Y.
    J Rheumatol; 2008 Jan 28; 35(1):31-4. PubMed ID: 18176989
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM.
    J Rheumatol; 2005 Nov 28; 32(11):2109-15. PubMed ID: 16265687
    [Abstract] [Full Text] [Related]

  • 19. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group.
    Ann Rheum Dis; 2004 Sep 28; 63(9):1062-8. PubMed ID: 15082469
    [Abstract] [Full Text] [Related]

  • 20. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
    O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, Klein H, Moore GF.
    N Engl J Med; 1996 May 16; 334(20):1287-91. PubMed ID: 8609945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.